District Of Columbia 2023-2024 Regular Session

District Of Columbia Council Bill B25-0304

Introduced
6/5/23  
Engrossed
6/6/23  
Introduced
6/5/23  
Enrolled
6/27/23  
Engrossed
6/6/23  
Passed
7/10/23  
Enrolled
6/27/23  
Passed
9/29/23  
Passed
7/10/23  

Caption

Medical Cannabis Manufacturer Clarification Temporary Amendment Act of 2023

Impact

If enacted, B25-0304 would facilitate the expansion of the medical cannabis industry in the District of Columbia by allowing five specific cultivation centers to obtain manufacturer licenses. This could significantly impact state laws related to cannabis production and distribution, fostering growth in the medical cannabis sector. By potentially increasing the number of licensed manufacturers, the bill aims to enhance the access and availability of medical cannabis products to patients who require them for therapeutic purposes.

Summary

The Medical Cannabis Manufacturer Clarification Temporary Amendment Act of 2023, identified as B25-0304, is a legislative measure introduced to amend the existing Legalization of Marijuana for Medical Treatment Initiative of 1999. The primary focus of this bill is to clarify the licensing process for medical cannabis manufacturers by designating specific cultivation center registration applicants as eligible for manufacturer licenses. To qualify, these applicants must have scored 150 or more points during the registration application period held from November 29, 2021, to March 28, 2022, and must file a manufacturer license application by May 1, 2024.

Sentiment

The sentiment surrounding the bill has largely been positive, with support from various stakeholders within the medical cannabis community and regulatory bodies. Proponents see this measure as a necessary step to streamline the licensing process and promote the growth of the cannabis industry in the District. However, there may be some opposition based on concerns about the adequacy of regulation and potential market oversaturation. Yet, overall, the legislative discussions appear to lean towards a supportive view that prioritizes patient access to medical cannabis.

Contention

One notable point of contention regarding the bill revolves around the criteria established for eligible applicants, specifically the scoring system of 150 points. Critics may argue that this threshold could unfairly favor particular businesses over others, potentially leading to monopolistic conditions in the market. Additionally, discussions on the regulatory framework surrounding the cannabis industry, including manufacturing practices, safety standards, and patient protections, may also emerge as significant areas of debate as the bill progresses.

Companion Bills

No companion bills found.

Previously Filed As

DC B25-0720

Streatery Program and Endorsement Deadline Temporary Amendment Act of 2024

DC B25-0719

Streatery Program and Endorsement Deadline Emergency Amendment Act of 2024

DC PR26-0151

On-Premises and On-Site Extended Hours Program Emergency Declaration Resolution of 2025

DC PR25-1079

Streatery Program Endorsement Extension Emergency Declaration Resolution of 2024

DC B25-0303

Medical Cannabis Manufacturer Clarification Emergency Amendment Act of 2023

DC PR25-0675

Streatery Program and Endorsement Deadline Emergency Declaration Resolution of 2024

DC PR25-0254

Medical Cannabis Manufacturer Clarification Emergency Declaration Resolution of 2023

DC PR25-0754

Medical Cannabis License Clarification Congressional Review Emergency Declaration Resolution of 2024

Similar Bills

No similar bills found.